STOCKHOLM—Prostate cancer (PCa) patients who have blood type O have a lower risk of biochemical recurrence (BCR) after radical prostatectomy, Japanese researchers reported at the European Association of Urology 29th annual congress.
Yoshio Ohno, MD, and colleagues at Tokyo Medical University studied 555 PCa patients who underwent radical prostatectomy and did not receive neoadjuvant and/or adjuvant therapy. After a mean follow-up of 52 months, 166 patients (29.9%) experienced biochemical failure, for a 5-year BCR-free rate of 67.3%. Patients with blood type O had a 34.7% decrease in BCR risk compared with patients who had blood type A.
The investigators defined the time of BCR as the earliest date that the postoperative serum PSA levels increased to 0.2 ng/mL or higher.
The study is not the first to find an association between blood type and urinary cancer prognosis. Recently, Tobias Klatte, MD, of the Medical University of Vienna in Austria, and colleagues reported study findings showing that, among patients with non-muscle-invasive bladder urothelial carcinoma treated with transurethral bladder resection, those with blood type O had the highest rate of recurrence and progression. The findings were published online ahead of print in The Journal of Urology.